Conventional major histocompatibility complex (MHC) class 1 molecules transport peptides to the cell surface and thus enable cytotoxic T-cells to detect intracellular antigen. Because of their function in T cells recognition and extensive polymorphism, conventional class 1 molecules are critical determinants in bone marrow transplantation (BMT). Recent evidence has revealed that class 1-related molecules have variously modified immune defense functions and interact with distinct T-cell subsets. We have identified novel human MHC class 1 genes, MICA and MICB, which are evolutionarily conserved and regulated by the cell-stress response. At least MICA is polymorphic and encodes a cell surface glycoprotein mainly expressed in gastrointestinal epithelium. The characteristics of MICA and putative MICB molecules strongly suggest that they are recognized by a subset of intestinal intraepithelial lymphocytes (IEL). Studies proposed under Specific Aim 1 in this project are aimed at defining the immunological function of MICA and MICB, by further investigating their expression in normal tissues and inflammatory lesions, by isolation and functional characterization of the T-cells among IEL that specifically recognize these molecules, by correlating T-cell receptor sequence diversity with MICA polymorphism, and by purification and sequence analysis of bound peptide ligands. Studies proposed under Specific Aim 2 will investigate whether polymorphic MICA is a risk factor in acute gut graft-versus-host disease (GVHD) developing after BMT, in which the often fatal destruction of intestinal epithelium results from T- cell recognition of unknown tissue-specific target determinants. It is proposed to test whether mismatching of MICA alleles correlates with increased incidence of this disease, by molecular genetic typing of well characterized panels of unrelated donor and recipient pairs. Altogether, these studies will likely reveal a novel type of MHC class 1 ligand-T-cell interaction in the poorly defined human gut mucosal immune system. Moreover, they have the potential to provide new insights into the mechanisms underlying acute gut GVHD and may thus benefit the successful outcome of future marrow grafting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018221-22A1
Application #
6236410
Study Section
Project Start
1997-07-29
Project End
1998-03-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
22
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mielcarek, Marco; Storer, Barry E; Boeckh, Michael et al. (2009) Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 113:2888-94
Tseng, Li-Hui; Storer, Barry; Petersdorf, Effie et al. (2009) IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation 87:704-10
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Storek, Jan (2008) Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. Expert Opin Biol Ther 8:583-97
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Carpenter, Paul A; Hoffmeister, Paul; Chesnut 3rd, Charles H et al. (2007) Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant 13:683-90
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Alkindi, S; Deeg, J H; Flowers, M E D (2006) Recovery of normal autologous myelopoiesis after graft rejection following allogeneic bone marrow transplant for agnogenic myeloid metaplasia. Clin Lab Haematol 28:134-7

Showing the most recent 10 out of 692 publications